Chemistry:Bexirestrant
From HandWiki
Bexirestrant is a selective estrogen receptor degrader (SERD) which is being evaluated for the treatment of breast cancer. This orally bioavailable compound has demonstrated potent activity against both wild-type and mutant forms of the estrogen receptor (ER), addressing a critical need in overcoming resistance to current endocrine therapies.[1]
It is structurally characterized by an E-alkene linked to an azetidine core.
References
- ↑ "New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives". Acta Materia Medica 3 (1): 57–71. February 2024. doi:10.15212/amm-2024-0006. PMID 39373009.
 |  |
